Filing Details

Accession Number:
0001209191-20-039024
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2020-06-25 20:01:40
Reporting Period:
2020-01-03
Accepted Time:
2020-06-25 20:01:40
Original Submission Date:
2020-01-06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1610618 Cidara Therapeutics Inc. CDTX Biological Products, (No Disgnostic Substances) (2836) 461537286
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1639144 Paul Daruwala 6310 Nancy Ridge Drive
Suite 101
San Diego CA 92121
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-03 940 $3.42 52,592 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. This amendment is being filed to correct the number of shares sold which were underreported by 940 shares (i.e. a total of 3,280 shares were sold rather than 2,340) and to correct the end of period holdings to reduce such amount by 940 shares.
  2. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.